B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis.

Neurology

From the Neurovascular Research Laboratory (T.G.-B., D.G., A.B., J.M.), Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Spain; Department of Neurology (T.E.), Kliniken Südostbayern-Klinikum Traunstein, Germany; Department of Psychiatry and Psychotherapy (T.E.), Technische Universität München, Germany; Department of Cardiology (J.K.J.), Odense University, Denmark; Stroke Medicine (J.C.S.), Lincoln County Hospital, University of Nottingham, UK; Department of Stroke Medicine (K.S.), Kawasaki Medical School, Kurashiki City, Okayama, Japan; Department of Emergency Medicine (A.S.), School of Medicine, Duzce University, Turkey; Department of Neurology (X.C.), Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China; and Centre for Clinical Brain Sciences (W.N.W.), University of Edinburgh, UK.

Published: December 2013

Objective: To measure the association of B-type natriuretic peptide (BNP) and N-terminal fragment of BNP (NT-proBNP) with all-cause mortality after stroke, and to evaluate the additional predictive value of BNP/NT-proBNP over clinical information.

Methods: Suitable studies for meta-analysis were found by searching MEDLINE and EMBASE databases until October 26, 2012. Weighted mean differences measured effect size; meta-regression and publication bias were assessed. Individual participant data were used to estimate effects by logistic regression and to evaluate BNP/NT-proBNP additional predictive value by area under the receiver operating characteristic curves, and integrated discrimination improvement and categorical net reclassification improvement indexes.

Results: Literature-based meta-analysis included 3,498 stroke patients from 16 studies and revealed that BNP/NT-proBNP levels were 255.78 pg/mL (95% confidence interval [CI] 105.10-406.47, p = 0.001) higher in patients who died; publication bias entailed the loss of this association. Individual participant data analysis comprised 2,258 stroke patients. After normalization of the data, patients in the highest quartile had double the risk of death after adjustment for clinical variables (NIH Stroke Scale score, age, sex) (odds ratio 2.30, 95% CI 1.32-4.01 for BNP; and odds ratio 2.63, 95% CI 1.75-3.94 for NT-proBNP). Only NT-proBNP showed a slight added value to clinical prognostic variables, increasing discrimination by 0.028 points (integrated discrimination improvement index; p < 0.001) and reclassifying 8.1% of patients into correct risk mortality categories (net reclassification improvement index; p = 0.003). Neither etiology nor time from onset to death affected the association of BNP/NT-proBNP with mortality.

Conclusion: BNPs are associated with poststroke mortality independent of NIH Stroke Scale score, age, and sex. However, their translation to clinical practice seems difficult because BNP/NT-proBNP add only minor predictive value to clinical information.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854833PMC
http://dx.doi.org/10.1212/01.wnl.0000436937.32410.32DOI Listing

Publication Analysis

Top Keywords

b-type natriuretic
8
mortality stroke
8
additional predictive
8
publication bias
8
individual participant
8
participant data
8
integrated discrimination
8
discrimination improvement
8
net reclassification
8
reclassification improvement
8

Similar Publications

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by structural and functional abnormalities. Current management strategies, such as medications and septal reduction therapies, have significant limitations and risks. Recently, cardiac myosin inhibitors (CMIs) like mavacamten and aficamten have shown promise as noninvasive treatment options.

View Article and Find Full Text PDF

Aims: Biomarkers are pivotal in the management of heart failure (HF); however, their lack of cardiac specificity could limit clinical utility. This study aimed to investigate the transcoronary changes and intracardiac production of these biomarkers.

Methods: Transcoronary gradients for B-type natriuretic peptide (BNP) and five novel biomarkers-galectin-3 (Gal-3), soluble suppression of tumourigenicity 2 (sST2), tissue inhibitor of metalloproteinase 1 (TIMP-1), growth differentiation factor 15 (GDF-15) and myeloperoxidase (MPO)-were determined using femoral artery (FA) and coronary sinus (CS) samples from 30 HF patients and 10 non-HF controls.

View Article and Find Full Text PDF

Background: Cardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. To screen biomarkers in patients with breast cancer who receive anthracycline-containing chemotherapy, we studied the behavior of six biomarkers during chemotherapy and their association with chemotherapy-related cardiac toxicity.

Methods: In a prospective cohort of 73 patients treated with anthracycline-containing chemotherapy, soluble suppression of tumorigenicity 2 (sST2), high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), myoglobin, creatine kinase isoenzyme MB, and heart-fatty acid binding protein were measured at baseline, during chemotherapy cycle (C1-C6).

View Article and Find Full Text PDF

Atrial and ventricular natriuretic peptides play an important role in the neurohormonal regulation of cardiac function. Plasma levels of these peptides may aid in the diagnosis and prognosis of different cardiac disorders, such as congestive heart failure, ischemic heart disease, and atrial fibrillation. However, the association between elevated pericardial fluid levels of natriuretic peptides and these clinical conditions has not been proven.

View Article and Find Full Text PDF

Different association of HDLC, apoA-I, and HDL-C/apoA-I with multiple outcomes in HFrEF patients.

Int J Cardiol

December 2024

Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, China; Nanhai Translational Innovation Center of Precision Immunology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Foshan 528200, China; Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou 510120, China. Electronic address:

Background: High-density lipoprotein-cholesterol (HDLC) has been considered a cardioprotective factor for several decades. However, its association with outcomes in patients with heart failure with reduced ejection fraction (HFrEF) remains controversial. We aimed to investigate the association of HDLC, apolipoprotein A-I (apoA-I), and the HDL-C/apoA-I ratio with multiple outcomes of HFrEF patients and establish prognostic models using machine learning methods.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!